Status: Not yet recruiting
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.
Participants needed: 535
Trial details
Phase: Phase 3Age: 55-85Biological sex: AllType: InterventionalSponsor: CerecinUpdated: Jul 1, 2026
Eligibility criteria
Mini Mental State Exam (MMSE) score between 14 to 24 [+5]
Has any medical/neurological/psychiatric condition, other than AD, that could ex... [+2]